Artificial intelligence (AI) software company Viz.ai has debuted new cerebral aneurysm detection software at the Society of Vascular and Interventional Neurology (SVIN) 2021 annual meeting in Phoenix.
Viz ANX, which is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA), uses AI to detect aneurysms on CT angiography scans and alert providers to the findings.
Also, the company debuted Viz SDH, a research-only algorithm that supports the EMBOLISE trial, in which researchers are evaluating the safety and efficacy of embolization of the middle meningeal artery using the Medtronic's Onyx liquid embolic system (LES) for the treatment of symptomatic subacute or chronic subdural hematoma.
Viz.ai's algorithm includes volumetric segmentation and measurement of the maximum thickness of the bleed and detects suspected SDH to alert clinicians to patients who might be candidates for the EMBOLISE study.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
